Ditch Partners With The CRIQ, Investissement Québec's World-Renowned Laboratory, For Nonclinical Testing

Written By Guest User

MONTREAL, QC/January, 2022 – Ditch Labs, Inc.’s partnership with the CRIQ led by Research Director and Partner Christelle Luce, Co-Founder and CTO Olivier Bourbonnais and Pharmacologist Mehdi El Hassani, will serve the objective of characterizing the aerosol generated by the DitchPen™. The company intends to present a toxicology report to the FDA and Health Canada in order to receive a Clinical Trial Authorization (Health Canada) and an Investigational New Drug approval (FDA).

Guest User
Previous

Ditch Receives $350,000 Of Funding From Québec’s Ministère de l’Économie et de l’Innovation (MEI), In Collaboration With MEDTEQ+ And PromptInnov
Next

Ditch Completes Successful Integration And Testing Of Its Second-Generation Alpha Product, Ready For Nonclinical Testing